LB Pharmaceuticals Inc Basic Shares Outstanding (Weighted Average)
LB Pharmaceuticals Inc (LBRX) reported Basic Shares Outstanding (Weighted Average) of 30.14 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- LB Pharmaceuticals Inc weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 30.14M shares, a 8299.33% increase year-over-year.
- LB Pharmaceuticals Inc weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 28.24M shares, a 7771.66% increase year-over-year.
- LB Pharmaceuticals Inc weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 25.59M shares, a 7024.70% increase year-over-year.
- LB Pharmaceuticals Inc weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 5.81M shares, a 1517.15% increase year-over-year.
- LB Pharmaceuticals Inc weighted average number of shares outstanding, basic for fiscal 2025 was 8.05M shares, a 2145.81% increase from fiscal 2024.
- LB Pharmaceuticals Inc weighted average number of shares outstanding, basic for fiscal 2024 was 358.23K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 30.14M shares 10-Q · filed 2026-08-11 | 29.19M shares 10-Q · filed 2026-08-11 | 27.99M shares derived: average of 3 quarters · filed 2026-08-11 | 22.45M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 28.24M shares 10-Q · filed 2026-05-12 | 26.92M shares derived: average of 2 quarters · filed 2026-05-12 | 19.88M shares derived: average of 3 quarters · filed 2026-05-12 | 15.00M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 25.59M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 15.70M shares derived: average of 2 quarters · filed 2026-03-26 | 10.59M shares derived: average of 3 quarters · filed 2026-08-11 | 8.05M shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 5.81M shares 10-Q · filed 2025-11-06 | 3.08M shares derived: average of 2 quarters · filed 2026-08-11 | 2.20M shares 10-Q · filed 2025-11-06 | 1.72M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 358.81K shares 10-Q · filed 2026-08-11 | 358.79K shares 10-Q · filed 2026-08-11 | 358.94K shares derived: average of 3 quarters · filed 2026-08-11 | 358.98K shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 358.78K shares 10-Q · filed 2026-05-12 | 359.01K shares derived: average of 2 quarters · filed 2026-05-12 | 359.03K shares derived: average of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | 359.24K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 359.16K shares derived: average of 2 quarters · filed 2026-03-26 | 358.23K shares 10-K · filed 2026-03-26 | |
| 2024-09-30 | 359.08K shares 10-Q · filed 2025-11-06 | 357.89K shares 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |